Palexia (Tapentadol)

Tapentadol, the active ingredient in Palexia, is an opioid analgesic presented as a tablet for oral use. It is indicated for the management of moderate to severe acute pain in adult patients when alternative treatments are inadequate.

GNH USA supplies Palexia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Palexia is an opioid analgesic that acts on the central nervous system to relieve pain associated with several conditions. - Acute postoperative pain: Provides effective relief following surgical procedures. - Chronic musculoskeletal pain: Helps manage persistent pain from conditions such as osteoarthritis. - Cancer‑related pain: Used as part of a multimodal regimen for severe cancer pain when other opioids are insufficient.

Tapentadol may cause a range of adverse reactions, most of which are mild to moderate and resolve after continued use or dose adjustment.

Common Side Effects: - Nausea: Feeling of sickness often accompanied by an urge to vomit. - Constipation: Reduced bowel movements or difficulty passing stool. - Dizziness: Light‑headed sensation, especially when standing quickly. - Headache: Mild to moderate pain in the head region. - Somnolence: Increased sleepiness or fatigue. - Dry mouth: Reduced salivation leading to a dry oral cavity.

Serious or Rare Side Effects: - Respiratory depression: Slowed or shallow breathing that can be life‑threatening. - Seizures: Uncontrolled electrical activity in the brain. - Severe hypotension: Markedly low blood pressure causing faintness. - Allergic reactions: Rash, itching, swelling, or anaphylaxis. - Dependence or abuse potential: Risk of developing physical or psychological dependence. - Adrenal insufficiency: Uncommon hormonal deficiency affecting stress response.

When prescribing Tapentadol, clinicians should consider several safety measures to minimize risk. - Assess pain severity and prior opioid use: Determine if an opioid is appropriate. - Review patient medical history: Identify respiratory, hepatic, renal or CNS disorders. - Monitor for signs of misuse: Watch for craving, dose escalation or doctor shopping. - Avoid abrupt discontinuation: Taper dose gradually to prevent withdrawal. - Educate on concomitant CNS depressants: Counsel about increased sedation risk with alcohol or benzodiazepines. - Store at ambient temperature: Keep tablets in the original container, protect from moisture and heat.

Tapentadol interacts with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - CNS depressants (e.g., benzodiazepines, barbiturates): May cause profound sedation or respiratory depression. - MAO inhibitors: Can precipitate hypertensive crisis or serotonin syndrome. - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): Increase tapentadol plasma levels, raising toxicity risk.

Moderate Interactions (Monitor Closely): - Serotonergic agents (e.g., SSRIs, SNRIs): May increase risk of serotonin syndrome. - Antihistamines: Can enhance central nervous system depression. - Diuretics: May exacerbate hypotension when combined with tapentadol.